Abstract
Background: In the hospital environment, carbapenemase-producing Pseudomonas aeruginosa (CPPA) may lead to fatal patient infections. However, the transmission routes of CPPA often remain unknown. Therefore, this case study aimed to trace the origin of CPPA ST357, which caused a hospital-acquired pneumonia in a repatriated critically ill patient suffering from Guillain-Barré Syndrome in 2023. Methods: Antimicrobial susceptibility of the CPPA isolate for 30 single and combination therapies was determined by disk-diffusion, Etest or broth microdilution. Whole-genome sequencing was performed for three case CPPA isolates (one patient and two sinks) and four distinct CPPA ST357 patient isolates received in the Dutch CPPA surveillance program. Furthermore, 193 international P. aeruginosa ST357 assemblies were collected via three genome repositories and analyzed using whole-genome multi-locus sequence typing in combination with antimicrobial resistance gene (ARG) characterization. Results: A Dutch patient who carried NDM-1-producing CPPA was transferred from Kenya to the Netherlands, with subsequent dissemination of CPPA isolates to the local sinks within a month after admission. The CPPA case isolates presented an extensively drug-resistant phenotype, with susceptibility only for colistin and cefiderocol-fosfomycin. Phylogenetic analysis showed considerable variation in allelic distances (mean = 150, max = 527 alleles) among the ST357 isolates from Asia (n = 92), Europe (n = 58), Africa (n = 21), America (n = 16), Oceania (n = 2) and unregistered regions (n = 4). However, the case isolates (n = 3) and additional Dutch patient surveillance program isolates (n = 2) were located in a sub-clade of isolates from Kenya (n = 17; varying 15–49 alleles), the United States (n = 7; 21–115 alleles) and other countries (n = 6; 14–121 alleles). This was consistent with previous hospitalization in Kenya of 2/3 Dutch patients. Additionally, over half of the isolates (20/35) in this sub-clade presented an identical resistome with 9/17 Kenyan, 5/5 Dutch, 4/7 United States and 2/6 other countries, which were characterized by the bla NDM-1, aph(3’)-VI, ARR-3 and cmlA1 ARGs. Conclusion: This study presents an extensively-drug resistant subclone of NDM-producing P. aeruginosa ST357 with a unique resistome which was introduced to the Netherlands via repatriation of critically ill patients from Kenya. Therefore, the monitoring of repatriated patients for CPPA in conjunction with vigilance for the risk of environmental contamination is advisable to detect and prevent further dissemination.
Original language | English |
---|---|
Article number | 817 |
Number of pages | 13 |
Journal | BMC Infectious Diseases |
Volume | 24 |
Issue number | 1 |
DOIs | |
Publication status | Published - 13 Aug 2024 |
Keywords
- Pseudomonas aeruginosa
- Carbapenemase-producing
- Extensively-drug resistant
- Repatriation
- ST357
- Sink
- Humans
- Pseudomonas aeruginosa/genetics drug effects isolation & purification enzymology
- Netherlands/epidemiology
- beta-Lactamases/genetics metabolism
- Pseudomonas Infections/microbiology epidemiology drug therapy
- Drug Resistance, Multiple, Bacterial/genetics
- Anti-Bacterial Agents/pharmacology
- Whole Genome Sequencing
- Microbial Sensitivity Tests
- Kenya/epidemiology
- Multilocus Sequence Typing
- Bacterial Proteins/genetics metabolism
- Male